Efficacy of oral levofloxacin monotherapy against low-risk FN in                    patients with malignant lymphoma who received chemotherapy using the CHOP                    regimen

Ai Mogi; Hidenori Sasaki; Yuta Nakashima; Shotaro Chinen; Masanao Ishizu; Toshihiro Tanaka; Tohru Takata; Yasushi Takamatsu

doi:10.3960/jslrt.20008

この記事には本公開記事があります。本公開記事を参照してください。
引用する場合も本公開記事を引用してください。

Efficacy of oral levofloxacin monotherapy against low-risk FN in patients with malignant lymphoma who received chemotherapy using the CHOP regimen

Ai Mogi , Hidenori Sasaki, Yuta Nakashima, Shotaro Chinen, Masanao Ishizu, Toshihiro Tanaka, Tohru Takata, Yasushi Takamatsu

著者情報

Ai Mogi 責任著者
Division of Medical Oncology, Hematology and Infection Disease, Department of Internal Medicine, Fukuoka University, Fukuoka, Japan
Hidenori Sasaki
Division of Medical Oncology, Hematology and Infection Disease, Department of Internal Medicine, Fukuoka University, Fukuoka, Japan
Yuta Nakashima
Division of Medical Oncology, Hematology and Infection Disease, Department of Internal Medicine, Fukuoka University, Fukuoka, Japan
Shotaro Chinen
Division of Medical Oncology, Hematology and Infection Disease, Department of Internal Medicine, Fukuoka University, Fukuoka, Japan
Masanao Ishizu
Division of Medical Oncology, Hematology and Infection Disease, Department of Internal Medicine, Fukuoka University, Fukuoka, Japan
Toshihiro Tanaka
Division of Medical Oncology, Hematology and Infection Disease, Department of Internal Medicine, Fukuoka University, Fukuoka, Japan
Tohru Takata
Division of Medical Oncology, Hematology and Infection Disease, Department of Internal Medicine, Fukuoka University, Fukuoka, Japan
Yasushi Takamatsu
Division of Medical Oncology, Hematology and Infection Disease, Department of Internal Medicine, Fukuoka University, Fukuoka, Japan

キーワード: febrile neutropenia, levofloxacin, malignant lymphoma, CHOP

ジャーナルオープンアクセス早期公開

論文ID: 20008

DOI https://doi.org/10.3960/jslrt.20008

この記事には本公開記事があります。

The final version of this article is now available: Vol. 60 (2020), No. 3 pp. 73-77

詳細

抄録

The safety and feasibility of oral fluoroquinolone monotherapy in patients with low-risk febrile neutropenia (FN) were demonstrated in recent studies. Levofloxacin (LVFX) is a commonly prescribed antibiotic; however, evidence for its efficacy against FN is limited. Therefore, in this study, we retrospectively investigated the efficacy of LVFX against low-risk FN in patients with malignant lymphoma at our institution. Treatment success was defined as recovery from fever and neutropenia without alteration of the initial regimen. We recruited 29 patients between January 2013 and December 2018. The median age of the cohort was 64 (range: 21–87) years; 13 (44.8%) were aged over 65 years. In total, 22 patients had diffuse large B-cell lymphoma (DLBCL). Therapy was successful in 24 (82.8%) patients, whereas 5 had treatment failure requiring a change from LVFX to intravenous broad-spectrum antibacterial agents. No deaths related to FN were observed. Two patients required FN-related chemotherapy dose reduction in subsequent cycles. Although this cohort comprised many elderly patients, our study confirmed the efficacy of LVFX in patients with low-risk FN. This may improve the treatment of low-risk FN and malignant lymphoma.

責任著者(Corresponding author)

J-STAGEへの登録はこちら（無料）